But some phase 3 details are unconfirmed, and phase 2 data haven’t shed light on the biggest question.

BDTX-1535 takes aim at PACC mutations and Tagrisso resistance.

What similarly acting projects are still unpartnered?

Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.

After a conference lacking the wow factor, biotech winners and losers emerge.